Central infusions of the recombinant human prolactin receptor antagonist, S179D-PRL, delay the onset of maternal behavior in steroid-primed, nulliparous female rats
Rs. Bridges et al., Central infusions of the recombinant human prolactin receptor antagonist, S179D-PRL, delay the onset of maternal behavior in steroid-primed, nulliparous female rats, ENDOCRINOL, 142(2), 2001, pp. 730-739
The expression of maternal behavior in the newly parturient rat is under en
docrine regulation. Blocking endogenous PRL secretion with bromocriptine de
lays the normal rapid expression of maternal care shown toward foster young
in steroid-primed virgin female rats. The recent development of the PRL re
ceptor antagonist S179D-PRL, a mutant of human PRL in which the serine resi
due at the 179 position is replaced with aspartate, provides a potentially
useful tool to examine the role of PRL in neural processing. In the present
report, three experiments were conducted that examined the effects of this
PRL antagonist on the induction of maternal behavior. In each experiment,
ovariectomized, nulliparous rats were treated sequentially with SILASTIC ca
psules implanted sc with progesterone (days 1-11) and estradiol (days 11-17
), a treatment that stimulates a rapid onset of maternal behavior in virgin
rats. On day 11, females mere implanted with Alzet miniosmotic pumps conne
cted to cannulae directed unilaterally at the lateral ventricle (Exp 1) or
bilaterally at the medial preoptic area (MPOA; Exp 2 and 3). Pumps containe
d either doses of S179D-PRL (0.115 or 1.15 mg/ml; Exp 1 and 2), wild-type h
uman PRL (1.15 mg/ml; Exp 3), or the saline vehicle (Exp 1-3). Testing for
maternal behavior began on day 12, a day after pump insertion, and animals
were tested daily for 6 days. Latencies to contact, retrieve, and group fos
ter test young were recorded. Administration of both the high and low doses
of S179D-PRL infused into the lateral ventricle (Exp 1) or MPOA (Exp 2) si
gnificantly delayed the onset of maternal behavior. In contrast, MPOA infus
ions of the control hormone, wildtype human PRL, in Exp 3 did not delay the
onset of maternal behavior. These findings support the concept that the ef
fects of S179D-PRL are caused by its actions as a PRL receptor antagonist r
ather than by a nonspecific effect of the protein. Overall, these results d
emonstrate the effectiveness of S179D-PRL acting at the level of the centra
l nervous system land, more specifically, within the MPOA) to regulate mate
rnal behavior, a PRL-mediated response.